Clinical data | |
---|---|
Trade names | Orathecin |
Other names | 9-Nitrocamptothecin 9-NC 9-nitro-20(S)-camptothecin Camptogen (19S)-19-Ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
Routes of administration | Oral (capsules) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 25–30% (rubitecan and 9-AC; in dogs) |
Protein binding | 97% (rubitecan), 65% (9-AC) |
Metabolism | Probably CYP-dependent |
Metabolites | 9-Aminocamptothecin (9-AC) |
Elimination half-life | 15–18 hours (rubitecan), 18–22 hours (9-AC) |
Excretion | Bile and feces (major proportion), urine (the minor one)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H15N3O6 |
Molar mass | 393.355 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rubitecan (INN, marketing name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, Inc.; a member of the Otsuka Group).